about
Generalized morphea and primary biliary cirrhosis coexisting in a male patientAssociation of Trabecular Bone Score with Inflammation and Adiposity in Patients with Psoriasis: Effect of Adalimumab TherapyCutaneous vasculitis associated with severe bacterial infections. A study of 27 patients from a series of 766 cutaneous vasculitis.Drug-associated cutaneous vasculitis: study of 239 patients from a single referral center.Significant sE-Selectin levels reduction after 6 months of anti-TNF-α therapy in non-diabetic patients with moderate-to-severe psoriasis.Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study.Histopathologic differences between cutaneous vasculitis associated with severe bacterial infection and cutaneous vasculitis secondary to other causes: study of 52 patients.Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy.Anti-TNF-α therapy reduces retinol-binding protein 4 serum levels in non-diabetic patients with psoriasis: a 6-month prospective study.Psoriasis and hypertension: a case-control study.Cutaneous infection with Alternaria triticina in a Bilateral lung transplant recipient.Redefining the therapeutic objective in psoriatic patients candidates for biological therapy.Cutaneous diffuse large B-cell lymphoma of the leg mimicking a chronic venous ulcerPerioral granulomatous reaction to DermalivePsoriasis and type 2 diabetes risk among psoriatic patients in a Spanish populationAnti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective studyPsoriasis vulgaris with or without arthritis and independent of disease severity or duration is a risk factor for hypercholesterolemiaRelationship of leptin with adiposity and inflammation and resistin with disease severity in psoriatic patients undergoing anti-TNF-alpha therapyEfficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practiceDisease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic ArthritisReal-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicenter study by the Spanish Psoriasis GroupOpportunistic virus infections in psoriasis patients: the safer alternative of apremilastRevisiting clinical differences between hypersensitivity vasculitis and Henoch-Schönlein purpura in adults from a defined population
P50
Q28268456-93DB33C1-22C6-4F66-9554-CD39534F6B61Q36936706-1B581859-3C1F-4BAC-8223-AC1A8C587523Q40154277-027E53BC-688D-4797-9B61-147FC1AF1616Q40190847-9E131D86-55F0-4BDA-8D5C-6303751A0CC0Q40207651-060334C2-91A9-44A2-9510-763497A6E273Q40513896-993B47FE-4361-47CE-86F6-9CE3FA4E14D9Q40724822-39591CF5-E0CA-49D0-9F06-7B0770427620Q41366968-444708F3-A577-43B2-8A41-9F36581E4772Q42472471-211C9426-2F15-4B7A-BA6A-056BDC8FF8F9Q44969254-932F47B7-D0C5-4909-891B-FF098018992DQ46944594-2B095BD1-7659-47B3-8A96-411F0FA7699AQ48368354-742A3F58-EED4-41E6-B4E6-FCEC6C42E1D9Q79836739-80BDAAE2-0DA6-4C6B-AD1C-89DBA585D729Q81004506-DE17638C-6B30-453C-B61B-5EB0A645D0B6Q84095460-B58BA587-C995-48B6-89BB-1B93690B8F97Q85888806-2BC0F698-0099-4E91-B7AF-C2CCA7F9DE90Q86624427-BB2C3FE7-3BAB-43BC-9849-FB9479C132CDQ87020353-D5829A69-C95C-491F-8AE9-F8C4D31EEF43Q87324847-7C2A3D68-44C4-4206-A390-B6A68B6C5B86Q91302345-A9E22D6A-4815-41DE-8BBB-334FEF5E7849Q91763932-7B8E1247-6F76-4BAB-A922-EEC26B1C1EA3Q95337279-A85E51F5-3EA1-4FCE-82BD-D60C85F04E64Q95527612-3BF523D6-3287-4A98-A348-D111B2BB0500
P50
description
investigador
@es
researcher
@en
name
Susana Armesto
@en
Susana Armesto
@nl
type
label
Susana Armesto
@en
Susana Armesto
@nl
prefLabel
Susana Armesto
@en
Susana Armesto
@nl
P31
P496
0000-0002-8081-0606